Although treatments targeting the EGFR, such as cetuximab, have demonstrated promise, the emergence of resistance in cancer cells, which typically occurs within 8–10 months of treatment initiation [[23], [24], [25], [26]], hampers their effectiveness. This evidence concerns the gene EGFR and cancer.